BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9493121)

  • 1. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
    Sever PS
    J Hypertens Suppl; 1997 Dec; 15(6):S9-12. PubMed ID: 9493121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients.
    McInnes GT; O'Kane KP; Istad H; Keinänen-Kiukaanniemi S; Van Mierlo HF
    J Hum Hypertens; 2000 Apr; 14(4):263-9. PubMed ID: 10805052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension.
    Melian EB; Jarvis B
    Drugs; 2002; 62(5):787-816. PubMed ID: 11929332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candesartan cilexetil. A review of its use in essential hypertension.
    McClellan KJ; Goa KL
    Drugs; 1998 Nov; 56(5):847-69. PubMed ID: 9829158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators.
    Oparil S; Levine JH; Zuschke CA; Gradman AH; Ripley E; Jones DW; Hardison JD; Cushing DJ; Prasad R; Michelson EL
    Am J Cardiol; 1999 Aug; 84(3):289-93. PubMed ID: 10496437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators.
    Reif M; White WB; Fagan TC; Oparil S; Flanagan TL; Edwards DT; Cushing DJ; Michelson EL
    Am J Cardiol; 1998 Oct; 82(8):961-5. PubMed ID: 9794352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
    Ogihara T; Arakawa K
    J Hum Hypertens; 1999 Jan; 13 Suppl 1():S27-31; discussion S33-4. PubMed ID: 10076918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Candesartan cilexetil: an update of its use in essential hypertension.
    Easthope SE; Jarvis B
    Drugs; 2002; 62(8):1253-87. PubMed ID: 12010090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.
    Himmelmann A; Keinänen-Kiukaanniemi S; Wester A; Redón J; Asmar R; Hedner T;
    Blood Press; 2001; 10(1):43-51. PubMed ID: 11332334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension.
    Oparil S
    Am J Cardiol; 1999 Nov; 84(10A):35S-41S. PubMed ID: 10588093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S; Stirling AL
    Am J Health Syst Pharm; 2000 Apr; 57(8):739-46. PubMed ID: 10786259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
    Malmqvist K; Kahan T; Dahl M
    Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan.
    Andersson OK; Neldam S
    Blood Press; 1998 Jan; 7(1):53-9. PubMed ID: 9551878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension--comparison with a combination of losartan and hydrochlorothiazide.
    Ohma KP; Milon H; Valnes K
    Blood Press; 2000; 9(4):214-20. PubMed ID: 11055474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA; McVoy HJ; Kaul AF
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.
    Kloner RA; Weinberger M; Pool JL; Chrysant SG; Prasad R; Harris SM; Zyczynski TM; Leidy NK; Michelson EL;
    Am J Cardiol; 2001 Mar; 87(6):727-31. PubMed ID: 11249891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC Trial.
    Association of Black Cardiologists (ABC) Candesartan Study Group
    Heart Dis; 2000; 2(6):392-9. PubMed ID: 11728289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS
    Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Candesartan Cilexetil Study Investigators.
    Zuschke CA; Keys I; Munger MA; Carr AA; Marinides GN; Flanagan TL; Cushing DJ; Hayes JL; Michelson EL
    Clin Ther; 1999 Mar; 21(3):464-74. PubMed ID: 10321416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.